HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006-2019.

Abstract
Definitions of resistance in multidrug-resistant tuberculosis (MDR TB) and extensively drug-resistant tuberculosis (XDR TB) have been updated. Pre-XDR TB, defined as MDR TB with additional resistance to fluoroquinolones, and XDR TB, with additional resistance to bedaquiline or linezolid, are frequently associated with treatment failure and toxicity. We retrospectively determined the effects of pre-XDR/XDR TB resistance on outcomes and safety of MDR TB treatment in France. The study included 298 patients treated for MDR TB at 3 reference centers during 2006-2019. Of those, 205 (68.8%) cases were fluoroquinolone-susceptible MDR TB and 93 (31.2%) were pre-XDR/XDR TB. Compared with fluoroquinolone-susceptible MDR TB, pre-XDR/XDR TB was associated with more cavitary lung lesions and bilateral disease and required longer treatment. Overall, 202 patients (67.8%) had favorable treatment outcomes, with no significant difference between pre-XDR/XDR TB (67.7%) and fluoroquinolone-susceptible MDR TB (67.8%; p = 0.99). Pre-XDR/XDR TB was not associated with higher risk for serious adverse events.
AuthorsYousra Kherabi, Mathilde Fréchet-Jachym, Christophe Rioux, Yazdan Yazdanpanah, Frédéric Méchaï, Valérie Pourcher, Jérôme Robert, Lorenzo Guglielmetti, MDR-TB Management Group
JournalEmerging infectious diseases (Emerg Infect Dis) Vol. 28 Issue 9 Pg. 1796-1804 (09 2022) ISSN: 1080-6059 [Electronic] United States
PMID35997386 (Publication Type: Journal Article)
Chemical References
  • Antitubercular Agents
  • Fluoroquinolones
Topics
  • Antitubercular Agents (therapeutic use)
  • Extensively Drug-Resistant Tuberculosis (drug therapy, epidemiology)
  • Fluoroquinolones (therapeutic use)
  • France (epidemiology)
  • Humans
  • Mycobacterium tuberculosis
  • Retrospective Studies
  • Treatment Outcome
  • Tuberculosis, Multidrug-Resistant (drug therapy, epidemiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: